Abstract Library

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4652 Clinical response to somatostatin analogues in patients with DIPNECH: Findings from a new longitudinal registry

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) often presents with symptoms of cough and dyspnoea. DIPNECH remains understudied, and response to somatostatin analogues (SSAs) has been reported in a few small series.

Conference:

Presenting Author: Libre M

Authors: Libre M, Skotte E, Linden A, Wu J, Lippincott E,

Keywords: DIPNECH, somatostatin analogue,

#4636 Maximising the use of pancreatic enzyme replacement therapy (PERT) among patients with gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) and exocrine pancreatic insufficiency (EPI)

Introduction: Patients with GEPNENs frequently develop EPI due to surgical resection or use of somatostatin analogues (SSAs), however it is significantly underdiagnosed. Untreated EPI has significant impact on overall quality of life with patients with GEPNENs.

Conference:

Presenting Author:

Authors: Grewal U, Chandar A,

Keywords: Pancreatic insufficiency, Pancreatic enzyme replacement therapy, Gastroenteropancreatic neuroendocrine neoplasm,

#4535 Survival and toxicity outcomes of somatostatin analogues vs. other systemic therapies as first-line palliative treatment for patients with extrapulmonary G2 well-differentiated neuroendocrine tumours with a Ki-67 index between 10% and 20%

Introduction: In patients (pts) with an advanced well-differentiated (WD-NET) with a Ki-67>10% and ≤20% (“G2 high”), chemotherapy (ChT) or targeted therapies are the preferred first-line palliative options. Somatostatin analogues (SSAs) may offer an alternative, yet randomised evidence is lacking.

Conference:

Presenting Author:

Authors: Dawoodji A, Nuttall C, Eyong M, Farrell K, Barratt N,

Keywords: somatostatin analogue, SSA, non-SSA, Grade 2 well-differentiated neuroendocrine tumour, WD-NET,

#4473 Somatostatin analogue delayed the recrudescence of stomach NET: A real-world study

Introduction: Type 1 gastric NENs (g-NENs) are common and relapse easily. Somstostatin analogues (SSAs) can inhibit gastrin secretion and cell proliferation. While the usage of SSAs in g-NENs is still controversial.

Conference:

Presenting Author: Cai W

Authors: Cai W, Zhang J, Ge W, Hu H,

Keywords: somatostatin analogue, Type 1 gastric NEN, real-world study,